The MAP2K1 Knockout Raji Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population designed for the disruption of the endogenous MAP2K1 gene in a human B lymphocyte background. This product provides a heterogeneous population of Raji cells in which the MAP2K1 locus has been targeted using CRISPR/Cas9-mediated gene disruption, resulting in a functional loss-of-function model for MEK1. The polyclonal format preserves the diversity of editing events across the cell pool, enabling robust analysis of gene function without clonal selection bias.
The parental Raji cell line is an Epstein-Barr virus (EBV)-positive B lymphocyte line originally derived from a male patient with Burkitt’s lymphoma. Exhibiting lymphoblastoid morphology, Raji cells are extensively utilized in B cell biology, signal transduction, and hematological malignancy research. Their derivation from an aggressive lymphoma provides a clinically relevant context for studying oncogenic signaling pathways and therapeutic vulnerabilities in B cell malignancies.
MAP2K1 encodes MEK1, a dual-specificity kinase central to the RAS-RAF-MEK-ERK cascade. MEK1 activation occurs through RAF kinase (BRAF, RAF1, ARAF)-mediated phosphorylation of serine residues. Once activated, MEK1 dually phosphorylates ERK1 (MAPK3) and ERK2 (MAPK1) on threonine and tyrosine residues within their activation loops, triggering ERK nuclear translocation and phosphorylation of transcription factors ELK1, c-FOS, and MYC. Upstream signaling involves growth factor (EGF, FGF) stimulation of receptor tyrosine kinases (EGFR, FGFR), which recruit GRB2 and SOS to activate RAS (e.g., HRAS). Scaffolds such as KSR1 and the MP1/p14 complex facilitate efficient MEK1-ERK coupling. Disruption of MAP2K1 severs the RAS-RAF-to-ERK signaling relay, abolishing transcriptional programs that drive cell cycle regulators like Cyclin D1.
In the Raji B lymphocyte context, MEK1-dependent signaling is pivotal for integrating mitogenic and survival cues. Knockout of MAP2K1 in this EBV-transformed Burkitt’s lymphoma line likely abrogates ERK-mediated proliferation and anti-apoptotic programs, rendering cells refractory to growth factor stimulation and potentially sensitizing them to pharmacological MEK inhibition. This model is particularly relevant for dissecting B cell receptor and cytokine signaling networks, as well as for studying the contribution of the MAPK pathway to lymphomagenesis and drug resistance in hematological cancers.
Researchers can employ these MAP2K1 knockout polyclonal Raji cells for a wide spectrum of functional investigations, including cancer signaling studies, MAPK pathway dissection, and functional genomics using phospho-ERK Western blotting or flow cytometry. The cells are ideal for drug sensitivity profiling against MEK inhibitors (trametinib, cobimetinib) and assessing compensatory activation via phospho-proteomics. Proliferation (MTT, CellTiter-Glo) and apoptosis (Annexin V) assays quantify growth and survival defects, while RNA-seq identifies MEK1-dependent transcriptional programs. For further information or to discuss custom projects, contact Ascent Research.
